Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect ol losartan on circulating TNF alpha levels and left ventricular systolic performance in patients with heart failure
Autore:
Gurlek, A; Kilickap, M; Dincer, I; Dandachi, R; Tutkak, H; Oral, D;
Indirizzi:
Ankara Univ, Sch Med, Dept Cardiol, TR-06100 Ankara, Turkey Ankara Univ Ankara Turkey TR-06100 Dept Cardiol, TR-06100 Ankara, Turkey Ankara Univ, Sch Med, Dept Immunol, TR-06100 Ankara, Turkey Ankara Univ Ankara Turkey TR-06100 Dept Immunol, TR-06100 Ankara, Turkey
Titolo Testata:
JOURNAL OF CARDIOVASCULAR RISK
fascicolo: 5, volume: 8, anno: 2001,
pagine: 279 - 282
SICI:
1350-6277(200110)8:5<279:EOLOCT>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; CHRONIC-RENAL-FAILURE; ECHOCARDIOGRAPHIC ACOUSTIC QUANTIFICATION; ANGIOTENSIN-II; EJECTION FRACTION; EXERCISE CAPACITY; RANDOMIZED TRIAL; CLINICAL STATUS; PLASMA-LEVELS; WALL-MOTION;
Keywords:
ejection fraction; losartan; systolic function; tumor necrosis factor alpha;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Gurlek, A Birlik Mah 11,Sok 24-15 Cankaya, Ankara, Turkey Birlik Mah 11,Sok 24-15 Cankaya Ankara Turkey Ankara, Turkey
Citazione:
A. Gurlek et al., "Effect ol losartan on circulating TNF alpha levels and left ventricular systolic performance in patients with heart failure", J CARD RISK, 8(5), 2001, pp. 279-282

Abstract

Background Tumor necrosis factor alpha (TNF alpha) plays an important rolein the pathophysiology of heart failure. Recent studies have shown a beneficial effect of losartan in these patients. However, the effect of losartanon TNF alpha levels in heart failure has not yet been studied. We evaluated the effect of losartan on circulating TNF alpha levels and ejection fraction (EF) in patients with congestive heart failure. Methods Forty patients with heart failure and EF less than or equal to 40%were enrolled into the study. All of the patients have been given diureticand digitalis therapy. Twenty patients were given losartan (50 mg/d) (Group I, 10 women, 10 men, 12 dilated cardiomyopathy, 8 ischemic heart disease,mean age 64.9 +/- 8.9), and another 20 patients were not given losartan because of hypotension or renal dysfunction (Group II, 13 men, 7 women, 10 dilated cardiomyopathy, 10 ischemic heart disease, mean age 61.2 +/- 10.5). EF was measured at the initial evaluation and on the fifteenth day of the therapy by echocardiographic examination using an acoustic quantification method. Circulating TNF alpha levels were also measured at the initial evaluation and on the fifteenth day of therapy by the ELISA method. Results Losartan significantly increased EF and decreased TNF alpha (EF increased from 29.4 +/- 7.3% to 36.0 +/- 8.5%, P < 0.001, and TNF alpha decreased from 39.2 +/- 37.4 pg/ml to 27.0 +/- 30.0 pg/ml, P < 0.05). Changes inTNF alpha levels and EF were not found to be correlated (r=-0.28, P=0.24). However, in the control group, EF and TNF alpha levels were similar at baseline and at the fifteenth day (EF 31.4 +/- 8.1% vs 31.7 +/- 7.8%, P=0.1, and TNF alpha 91.5 +/- 86.0 pg/ml vs 110.0 +/- 80.7 pg/ml, P=0.1, respectively). Conclusions Losartan improves left ventricular systolic function and decreases TNF alpha level. The decreased TNF alpha level seems to be independentof EF. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:50:09